Oncology

Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars

May 15th 2024

By Skylar Jeremias

At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.

Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars

May 2nd 2024

By Skylar Jeremias

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.

FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi

April 29th 2024

By Skylar Jeremias

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast and gastric cancers.

AON Saves Over $243 Million With High Biosimilar Adoption

April 22nd 2024

By Skylar Jeremias

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.

Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032

April 11th 2024

By Skylar Jeremias

The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.

Biosimilar Business Recap: BI Layoffs; Teva, mAbxience Partnership; Phase 3 Keytruda Biosimilar Trial

April 8th 2024

By Skylar Jeremias

After poor sales for its adalimumab biosimilar, Boehringer Ingelheim (BI) announces layoffs; Teva Pharmaceuticals and mAbxience partner on an oncology biosimilar; Samsung Bioepis begins a phase 3 trial for a biosimilar referencing Keytruda (pembrolizumab).

Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs

March 29th 2024

By Skylar Jeremias

Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.

Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth

March 14th 2024

In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.

Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics

March 14th 2024

By Skylar Jeremias

Posters from Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit (AMCCBS) and the American Academy of Dermatology (AAD) highlight the benefits of incorporating biosimilars into electronic medical records and the biggest barriers for home injection of biologics.

Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio

March 13th 2024

By Skylar Jeremias

A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.